We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Nano-Magnets Produced by Bacteria Could Soon Target Tumors

By Biotechdaily staff writers
Posted on 27 Mar 2008
A new study by scientists in the United Kingdom and France has shown it is possible to customize the magnetic properties of tiny "nano” magnets produced by bacteria, and this technology could one day be developed to target cancer tumors.

The study is the work of Dr. More...
Sarah Staniland, from the School of Biological Sciences, University of Edinburgh (Scotland, UK), and colleagues, including Dr. Andrew Harrison, who is based at the Institut Laue-Langevin (Grenoble, France). The study was published in the early online issue in March 2, 2008 in the journal Nature Nanotechnology.

Some bacteria have the ability to digest iron into tiny nanoparticles of magnetite (Fe3O4) that are enclosed in lipid vesicles or membranes. These "magnetosomes,” as they are called, have considerable potential for medical use because of their greater biocompatibility and convenient narrow and uniform shape, compared to manmade versions. Bacteria use them like tiny compasses to help them search for environments rich in oxygen.

For use in medicine, a significant advantage could be gained if the magnetic properties of magnetosomes could be controlled, for instance, by chemically doping them; but before this study, that had not been demonstrated very successfully. Dr. Staniland and colleagues showed that they could inject the magnetosomes with three types of Magnetospirillum bacteria combined with cobalt.

The presence of cobalt in the magnetosomes increases their ability to stay magnetized when they are removed from a magnetic field. Measuring the coercive field necessary to reverse their magnetization showed that the increase in magnetic field strength conferred by the cobalt was between 36-45%, depending on the type of bacteria and the amount of cobalt absorbed.

Using a range of measuring techniques such as elemental analysis, X-ray absorption, and magnetic circular dichroism (effect of magnetic field on polarized light), Dr. Staniland and colleagues estimated the cobalt content of the magnetosomes to be between 0.2 and 1.4%.

The investigators concluded that their findings "provide an important advance in designing biologically synthesized nanoparticles with useful highly tuned magnetic properties.” The researchers speculated that magnetosomes that can stay magnetized longer could one day be used to target and destroy cancer cells. They could be guided to the tumor using magnetic force, and once there, by reversing the magnetic field they could be heated up and kill the cells. Another application could be to use them to transport drugs to the precise site of the tumor. Dr. Staniland reported that "for nanoparticles to be used in medicine you need them to be a very uniform size and shape and bacteria are very good for that.”

Explaining in a recent BBC News report, Dr. Staniland stated "you would move them with a normal magnetic field and then heat them with the opposing field.” Cancer experts reported nanotechnology like this is an exciting new field that could lead to new medical treatments, but the research is still very much at an early stage.


Related Links:
University of Edinburgh
Institut Laue-Langevin

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.